Pricing Log in Create free account
Saturday 17 October 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

210.05 4.37 −2.04%
Market cap
$13.9B
P/E
13.8×
Fwd P/E
17.3×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 69.82
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 6 2 — 4 2 1 5 3 1 2 3 2
Insider Ownership 1.33%

Capital & Financial Ratios $m

Market Cap 13,920.00
Revenue 4,601.29
Net Income 940.75
Free Cash Flow 1,416.54
Net Debt 2,151.60
Current Ratio 1.78 (at or above 1.5: strong)
Debt/Equity 0.91
P/E ratio 13.77
Fwd P/E 17.30
P/S ratio 2.89
P/B ratio 2.76
Past 5Y EPS Growth —
This Y EPS Growth 194.29% (at or above 15%: strong)
Next Y EPS Growth 5.59%
Next Y revenue growth 10.60% (at or above 10%: strong)
Next 5Y EPS Growth 51.35% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.4×, against a ten-year median of 4.0×; over the ten years it ranged from 2.3× in 2025 to 7.2× in 2017.
P/E against its own 10 years 9.01%
10-year low 10-year high
P/S against its own 10 years 42.83%
10-year low 10-year high
P/B against its own 10 years 57.13%
10-year low 10-year high
EV/Sales against its own 10 years 28.23%
10-year low 10-year high
EV/FCF against its own 10 years 11.87%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,626 2,993 2,442 2,200
Receivables 706 717 831 881
Inventory 597 480 417 443
Other 321 262 324 245
3,435 4,629 4,166 3,968
2023 2024 2025 Q'26
Payables 103 78 122 129
ST’ Debt 605 31 1,030 1,016
Other — — — —
1,537 1,039 2,243 2,231

Compound Annual Growth %

10y 5y 3y
Sales 12.41% 12.54% 5.26%
Cash Flow 9.81% 8.55% 2.15%
Earnings 0.00% 0.00% 0.00%
Book Value 10.45% 3.37% 11.86%

Revenue $m

Mar Jun Sep Dec Year
’26 1,069 1,208 — — —
’25 898 1,046 1,126 1,198 4,268
’24 902 1,024 1,055 1,088 4,069
’23 893 957 972 1,012 3,834
’22 814 933 941 972 3,659
’21 608 752 838 897 3,094
’20 535 562 601 666 2,364
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 408 416 — — —
’25 430 89 475 363 1,356
’24 267 331 399 399 1,396
’23 321 297 307 167 1,092
’22 209 303 418 342 1,272
’21 285 42 274 178 779
’20 273 183 258 186 900
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 389 321 — — —
’25 391 (782) 387 320 316
’24 250 324 388 385 1,348
’23 316 291 303 139 1,049
’22 172 222 423 (42) 774
’21 283 35 248 168 733
’20 53 77 245 146 520
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 4.43 2.78 — — —
’25 (1.52) (11.74) 4.08 3.21 (5.84)
’24 (0.23) 2.49 3.42 3.11 8.65
’23 1.04 1.52 2.14 1.42 6.10
’22 0.03 0.55 (0.31) (3.82) (3.58)
’21 2.09 (6.11) (0.86) (0.57) (5.52)
’20 (2.82) 2.06 2.64 2.33 4.22
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 95.80 109.14 113.52 116.52 86.88 117.64 125.36 111.25 99.06 95.49

Analyst estimates 2026–2028

Powerpack
High 160.00 163.75 184.00 154.24 166.00 189.00 169.98 160.96 134.17 182.99
People
People Employees 1,040 1,210 1,360 1,620 1,940 3,200 2,800 2,800 2,800 2,890
Revenue/emp, $m 1.43 1.34 1.39 1.33 1.22 0.97 1.31 1.37 1.45 1.48
Income, $m
Income, $m Revenue 1,488 1,619 1,891 2,162 2,364 3,094 3,659 3,834 4,069 4,268
Gross margin, % 92.92 93.19 93.57 94.08 93.70 85.76 85.23 88.64 89.05 88.21
EBT 532 441 529 454 275 (113) (373) 298 470 (628)
EBT margin, % 35.78 27.25 28.00 21.02 11.64 (3.65) (10.19) 7.77 11.56 (14.71)
Net income 397 488 447 523 239 (330) (224) 415 560 (356)
Depreciation 136 195 261 370 278 552 629 639 660 696
Per share, $
Per share, $ Revenue 24.59 26.97 31.53 38.09 42.42 51.84 58.51 60.58 65.80 69.98
Earnings 6.56 8.13 7.45 9.22 4.28 (5.52) (3.58) 6.55 9.06 (5.84)
Cash flow 9.79 11.55 13.32 13.68 16.15 13.04 20.34 17.25 22.57 22.23
Capex (3.03) (1.90) (1.39) (2.96) (6.81) (0.76) (7.97) (0.68) (0.78) (17.05)
Free cash flow 6.76 9.65 11.93 10.72 9.34 12.28 12.37 16.57 21.80 5.18
Book value 31.03 45.20 45.98 54.82 65.69 66.43 49.34 59.04 66.20 70.82
Shares, m 61 60 60 57 56 60 63 63 62 61
Valuation, ×
Valuation, × P/E 17.31 16.90 16.62 16.19 38.29 0.00 0.00 19.38 13.52 0.00
P/S 4.53 5.09 3.93 3.92 3.89 2.46 2.67 2.10 1.87 2.43
P/B 3.59 3.04 2.70 2.72 2.51 1.92 3.17 2.15 1.86 2.40
EV/Sales 5.61 5.70 4.34 4.16 3.87 4.22 4.00 3.16 2.64 3.11
EV/FCF 20.41 15.93 11.60 14.80 17.60 17.82 18.90 11.55 7.96 42.02
Cash, $m
Cash, $m Operating cash flow 592 693 799 776 900 779 1,272 1,092 1,396 1,356
Capex (183) (114) (84) (168) (379) (46) (498) (43) (48) (1,040)
Free cash flow 409 579 715 608 520 733 774 1,049 1,348 316
Balance, $m
Balance, $m Working capital 491 674 889 1,266 2,186 1,802 1,673 1,899 3,590 1,924
Total debt 2,030 1,581 1,596 1,607 2,095 6,050 5,724 5,713 6,109 5,358
Net debt 1,604 980 772 530 (38) 5,458 4,843 4,087 3,116 2,916
Shareholders’ equity 1,877 2,713 2,757 3,111 3,660 3,965 3,086 3,737 4,094 4,319
Returns, %
Returns, % ROA 9.76 9.83 8.66 9.74 3.95 (3.50) (1.94) 3.96 4.88 (3.01)
ROIC 10.62 8.95 10.89 9.14 6.52 1.13 (0.52) 4.62 6.21 (3.72)
ROE 22.83 21.25 16.35 17.84 7.05 (8.65) (6.36) 12.89 14.58 (8.47)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Jazz Pharmaceuticals PLC vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EXEL Exelixis, Inc. $15.6B 18.8× 16.7× +10.63% (above 0%: growing) +25.00% (above 0%: growing) +557.25% (above 0%: growing) 96.71% 39.51% Compare
ASND Ascendis Pharma A/S $14.9B 16.3× 13.0× +119.88% (above 0%: growing) n/m +2,335.93% (above 0%: growing) 91.85% 64.98% Compare
JAZZ Jazz Pharmaceuticals PLC $13.9B 13.8× 17.3× +15.55% (above 0%: growing) n/m +140.99% (above 0%: growing) 90.37% 20.54%
HALO Halozyme Therapeutics, Inc. $13.8B 34.6× 10.6× +47.67% (above 0%: growing) +44.12% (above 0%: growing) +141.18% (above 0%: growing) 83.54% 59.80% Compare
BBIO BridgeBio Pharma, Inc. $13.1B — (loss-making) — (loss-making) +120.39% (above 0%: growing) n/m +16.59% (above 0%: growing) 93.83% (43.94%) Compare
CORT Corcept Therapeutics Incorporated $12.3B 212× 139× +31.74% (above 0%: growing) +21.21% (above 0%: growing) −29.89% (below 0%: shrinking) 98.41% 16.12% Compare
SMMT Summit Therapeutics PLC $12.3B — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −112.80% (below 0%: shrinking) 0.00% 0.00% Compare
TECH Bio-Techne Corp $11.4B 62.0× 37.6× +1.33% (above 0%: growing) n/m −6.83% (below 0%: shrinking) 65.82% 23.13% Compare
BMRN BioMarin Pharmaceutical Inc. $10.9B 144× 16.1× +19.91% (above 0%: growing) −81.60% (below 0%: shrinking) −20.28% (below 0%: shrinking) 79.51% 11.21% Compare
Median of peers $12.7B 48.3× 16.4× +25.83% +23.11% +4.88% 87.70% 19.63%

All 614 Biotechnology stocks →

Jazz Pharmaceuticals PLC (JAZZ) key facts

  • Strength: Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
  • Jazz Pharmaceuticals PLC (JAZZ) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, JAZZ traded at $210.05, a market capitalization of $13.9 billion.
  • Return on equity was −8.47% and debt-to-equity 0.91.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.37 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Jazz Pharmaceuticals PLC (JAZZ) Latest News

12 Aug

Impact 5 ·
stockrow.com/JAZZ · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com